1: Srimal RC, Mason DF, Dhawan BN. Pharmacological studies on 3-[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6-hexahydro-1 (H)-pyrazino(1,2-a) quinoline hydrochloride (compound 69/183). Part II: Effect on cardiac dynamics. Arzneimittelforschung. 1978;28(7):1092-5. PMID: 582695.
2: Singh GB, Srimal RC, Dhawan BN. Pharmacological studies on 3-[gamma-(p-fluoro benzoyl)propyl]-2,3,4,4a,5,6-hexahydro-1-(H)-pyrazino(1,2-a)quinoline hydrochloride (compound 69/183). Part IV: other CNS effects and acute toxicity. Arzneimittelforschung. 1978;28(9):1641-4. PMID: 582569.
3: Singh GB, Srimal RC, Dhawan BN. Pharmacological studies on 3-[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6-hexahydro-1-(H)-pyrazino ]1,2-a] quinoline hydrochloride (compound 69/183). Part III: Assessment of tranquillising activity. Arzneimittelforschung. 1978;28(8):1403-6. PMID: 37855.
4: Singh GB, Nityanand S, Srimal RC, Rao VA, Jain PC, Dhawan BN. Antihypertensive and central nervous system depressant properties of 3-(gamma-p- fluorobenzoyl propyl) 2,3,4,4a,5,6-hexahydro-1(H)-pyrazino(1,2-a) quinoline hydrochloride (compound 69-183, centpyraquin). Experientia. 1973 Dec;29(12):1529-30. doi: 10.1007/BF01943898. PMID: 4203916.
5: Singh GB, Srimal RC, Nityanand S, Dhawan BN. Pharmacological studies on 3-[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6-hexahydro-1-(H)-pyrazino (1,2-a) quinoline (compound 69/183). Part I: Hypotensive activity. Arzneimittelforschung. 1978;28(7):1087-91. PMID: 114185.